Algorithm of Pulmonary Arterial Hypertension

[1]  M. Clozel,et al.  Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension. , 2015, Journal of medicinal chemistry.

[2]  R. Speich,et al.  Efficacy of exercise training in pulmonary arterial hypertension associated with congenital heart disease. , 2013, International journal of cardiology.

[3]  Z. Jing,et al.  Macitentan and morbidity and mortality in pulmonary arterial hypertension. , 2013, The New England journal of medicine.

[4]  M. Humbert,et al.  Riociguat for the treatment of pulmonary arterial hypertension. , 2013, The New England journal of medicine.

[5]  L. Chan,et al.  Effect of aerobic exercise training on fatigue and physical activity in patients with pulmonary arterial hypertension. , 2013, Respiratory medicine.

[6]  H. Ghofrani,et al.  Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study , 2013, Circulation.

[7]  Z. Jing,et al.  Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension: A Randomized, Controlled Trial , 2013, Circulation.

[8]  L. Chan,et al.  Benefits of intensive treadmill exercise training on cardiorespiratory function and quality of life in patients with pulmonary hypertension. , 2013, Chest.

[9]  V. McLaughlin.  Has the 6-min walk distance run its course? , 2012, Chest.

[10]  D. Badesch,et al.  Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. , 2012, Chest.

[11]  T. Fleming,et al.  Biomarkers and surrogate endpoints in clinical trials , 2012, Statistics in medicine.

[12]  A. Rahmel,et al.  The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[13]  P. Gargiulo,et al.  Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. , 2012, Journal of the American College of Cardiology.

[14]  T. Welte,et al.  Extracorporeal membrane oxygenation in awake patients as bridge to lung transplantation. , 2012, American journal of respiratory and critical care medicine.

[15]  C. Fischer,et al.  Exercise training in pulmonary arterial hypertension associated with connective tissue diseases , 2012, Arthritis Research & Therapy.

[16]  A. Torbicki,et al.  829 Care Organisation for Pulmonary Arterial Hypertension in Developed Countries: A Survey , 2012 .

[17]  S. Keshavjee,et al.  Outcome of patients with pulmonary arterial hypertension referred for lung transplantation: a 14-year single-center experience. , 2012, The Journal of thoracic and cardiovascular surgery.

[18]  A. Torbicki,et al.  Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension , 2012, European Respiratory Journal.

[19]  R. Speich,et al.  Safety and efficacy of exercise training in various forms of pulmonary hypertension , 2012, European Respiratory Journal.

[20]  M. Humbert,et al.  Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[21]  M. Humbert,et al.  Pregnancy outcomes in pulmonary arterial hypertension in the modern management era , 2012, European Respiratory Journal.

[22]  Shengshou Hu,et al.  Combination Therapy in Pulmonary Arterial Hypertension: A Meta-Analysis , 2011, Cardiology.

[23]  T. Welte,et al.  The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension , 2011, European Respiratory Journal.

[24]  Z. Jing,et al.  Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. , 2011, American journal of respiratory and critical care medicine.

[25]  S. Rosenkranz,et al.  Effect of Exercise and Respiratory Training on Clinical Progression and Survival in Patients with Severe Chronic Pulmonary Hypertension , 2011, Respiration.

[26]  R. Naeije,et al.  Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension. , 2011, British journal of clinical pharmacology.

[27]  H. Ghofrani,et al.  Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. , 2010, American journal of respiratory and critical care medicine.

[28]  R. Naeije,et al.  Optimising the management of pulmonary arterial hypertension patients: emergency treatments , 2010, European Respiratory Review.

[29]  A. Chapelier,et al.  Long-term outcome of double-lung and heart-lung transplantation for pulmonary hypertension: a comparative retrospective study of 219 patients. , 2010, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[30]  A. Manes,et al.  Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses , 2010, European heart journal.

[31]  Horst Olschewski,et al.  Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. , 2010, Journal of the American College of Cardiology.

[32]  K. Iversen,et al.  Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. , 2010, European heart journal.

[33]  L. Shapiro,et al.  Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[34]  M. Raza.  Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension , 2010 .

[35]  N. Westerhof,et al.  Effects of exercise training in patients with idiopathic pulmonary arterial hypertension , 2009, European Respiratory Journal.

[36]  P. Corris,et al.  Interventional and surgical modalities of treatment in pulmonary hypertension. , 2009, Journal of the American College of Cardiology.

[37]  H. Ghofrani,et al.  Updated evidence-based treatment algorithm in pulmonary arterial hypertension. , 2009, Journal of the American College of Cardiology.

[38]  B. Brundage,et al.  Tadalafil Therapy for Pulmonary Arterial Hypertension , 2009, Circulation.

[39]  A. Branzi,et al.  A meta-analysis of randomized controlled trials in pulmonary arterial hypertension , 2008, European heart journal.

[40]  D. Badesch,et al.  Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. , 2006, Chest.

[41]  M. Cheitlin.  Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients with Pulmonary Arterial Hypertension: A Randomized Trial , 2009 .

[42]  T. Fleming,et al.  Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension (Annals of Internal Medicine (2008) 149 (521-530)) , 2008 .

[43]  T. Fleming,et al.  Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. , 2008, Annals of internal medicine.

[44]  M. Zenati,et al.  Long-term outcome of lung and heart-lung transplantation for idiopathic pulmonary arterial hypertension. , 2008, The Annals of thoracic surgery.

[45]  G. Simonneau,et al.  Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial , 2008, The Lancet.

[46]  Neil A. Gilchrist.  Ambrisentan for the Treatment of Pulmonary Arterial Hypertension , 2008 .

[47]  G. Baumann,et al.  Long-term follow-up of a fenestrated Amplatzer atrial septal occluder in pulmonary arterial hypertension. , 2007, Chest.

[48]  Grzegorz Opolski,et al.  Atrial septostomy in treatment of end-stage right heart failure in patients with pulmonary hypertension. , 2007, Chest.

[49]  R. Barst,et al.  Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. , 2006, American journal of respiratory and critical care medicine.

[50]  F. Herth,et al.  Exercise and Respiratory Training Improve Exercise Capacity and Quality of Life in Patients With Severe Chronic Pulmonary Hypertension , 2006, Circulation.

[51]  M. Hoeper,et al.  Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension , 2006, European Respiratory Journal.

[52]  Marshall I Hertz,et al.  Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult lung and heart-lung transplantation report--2006. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[53]  M. Gatzoulis,et al.  Bosentan Therapy in Patients With Eisenmenger Syndrome: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study , 2006, Circulation.

[54]  S. Malhotra,et al.  A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. , 2006, American heart journal.

[55]  M. Pillinger,et al.  Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension , 2006 .

[56]  Marshall I Hertz,et al.  Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult lung and heart-lung transplantation report--2006. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[57]  D. Badesch,et al.  Ambrisentan therapy for pulmonary arterial hypertension. , 2005, Journal of the American College of Cardiology.

[58]  J. Wharton,et al.  Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. , 2005, American journal of respiratory and critical care medicine.

[59]  M. de la Morena,et al.  Repair of congenital heart lesions combined with lung transplantation for the treatment of severe pulmonary hypertension: a 13-year experience. , 2005, The Journal of thoracic and cardiovascular surgery.

[60]  Thomas R Fleming,et al.  Surrogate endpoints and FDA's accelerated approval process. , 2005, Health affairs.

[61]  E. Fiumana,et al.  Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells , 2005, Basic Research in Cardiology.

[62]  W. Seeger,et al.  Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. , 2004, Journal of the American College of Cardiology.

[63]  M. Humbert,et al.  Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 , 2004, European Respiratory Journal.

[64]  W. Seeger,et al.  Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[65]  B. Raju,et al.  Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. , 2004, Journal of the American College of Cardiology.

[66]  A. Branzi,et al.  The endothelin system in pulmonary arterial hypertension. , 2004, Cardiovascular research.

[67]  K. Wasserman,et al.  Erratum: Beraprost therapy for pulmonary arterial hypertension (Journal of the American College of Cardiology (2003) 41 (2119-2125)) , 2003 .

[68]  K. Wasserman,et al.  Beraprost therapy for pulmonary arterial hypertension. , 2003, Journal of the American College of Cardiology.

[69]  A. Branzi,et al.  Prostanoids for Pulmonary Arterial Hypertension , 2003, American journal of respiratory medicine : drugs, devices, and other interventions.

[70]  E. Trulock,et al.  The Registry of the International Society for Heart and Lung Transplantation: Twentieth Official adult lung and heart-lung transplant report--2003. , 2003, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[71]  G. Simonneau,et al.  Inhaled iloprost for severe pulmonary hypertension , 2002 .

[72]  A. Shillington,et al.  Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy , 2002, Circulation.

[73]  Gilles Garcia,et al.  Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. , 2002, Journal of the American College of Cardiology.

[74]  S. Keshavjee,et al.  Heart-lung or lung transplantation for Eisenmenger syndrome. , 2002, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[75]  M. Humbert,et al.  Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. , 2002, Journal of the American College of Cardiology.

[76]  S. Rich,et al.  Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.

[77]  Avid,et al.  BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION , 2002 .

[78]  G. Simonneau,et al.  EFFECTS OF THE DUAL ENDOTHELIN RECEPTOR ANTAGONIST BOSENTAN IN PATIENTS WITH PULM HT: A RANDOMIZED PLACEBO CONTROLLED STUDY , 2001 .

[79]  Stuart Rich,et al.  Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.

[80]  N. Powe,et al.  The association between hospital volume and survival after acute myocardial infarction in elderly patients. , 1999, The New England journal of medicine.

[81]  L. Sharples,et al.  Long term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension , 1998, Heart.

[82]  J. Sandoval,et al.  Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. , 1998, Journal of the American College of Cardiology.

[83]  S. Rich,et al.  Pulmonary hypertension--advances in medical and surgical interventions. , 1998, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[84]  B. Groves,et al.  A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.

[85]  R. Barst,et al.  FOR THE PRIMARY PULM HYPERTENSION STUDY GROUP. A COMPARISON OF CONTINUOUS INTRAVENOUS EPOPROSTENOL (PROSTACYCLIN) WITH CONVENTIONAL THERAPY FOR PRIMARY PULMONARY HYPERTENSION , 1996 .

[86]  C. Benjamin,et al.  Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. , 1995, Molecular pharmacology.

[87]  A Giaid,et al.  Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. , 1995, The New England journal of medicine.

[88]  D. Stewart,et al.  Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.

[89]  B. Groves,et al.  An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. , 1992, The New England journal of medicine.

[90]  D. Stewart,et al.  Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? , 1991, Annals of internal medicine.

[91]  J. H. Diehl,et al.  Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol): Results of a Randomized Trial , 1990 .